216 related articles for article (PubMed ID: 15869731)
1. Prolymphocytic leukemia.
Absi A; Hsi E; Kalaycio M
Curr Treat Options Oncol; 2005 May; 6(3):197-208. PubMed ID: 15869731
[TBL] [Abstract][Full Text] [Related]
2. Current treatment options in prolymphocytic leukemia.
Robak T; Robak P
Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
4. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
[TBL] [Abstract][Full Text] [Related]
6. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.
Döhner H; Ho AD; Thaler J; Stryckmans P; Sonneveld P; de Witte T; Lechner K; Lauria F; Bödewadt-Radzun S; Suciu S
J Natl Cancer Inst; 1993 Apr; 85(8):658-62. PubMed ID: 8468724
[TBL] [Abstract][Full Text] [Related]
7. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
8. How I treat prolymphocytic leukemia.
Dearden C
Blood; 2012 Jul; 120(3):538-51. PubMed ID: 22649104
[TBL] [Abstract][Full Text] [Related]
9. T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
[TBL] [Abstract][Full Text] [Related]
11. Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia.
Vartholomatos G; Tsiara S; Christou L; Panteli A; Kaiafas P; Bourantas KL
Acta Haematol; 1999; 102(2):94-8. PubMed ID: 10529513
[TBL] [Abstract][Full Text] [Related]
12. Typhlitis as a complication of alemtuzumab therapy.
Marie I; Robaday S; Kerleau JM; Jardin F; Levesque H
Haematologica; 2007 May; 92(5):e62-3. PubMed ID: 17562596
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
[TBL] [Abstract][Full Text] [Related]
14. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
[TBL] [Abstract][Full Text] [Related]
16. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
Chaar BT; Petruska PJ
Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
[No Abstract] [Full Text] [Related]
17. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Tam CS; O'Brien S; Lerner S; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou AM; Kantarjian H; Wierda WG
Leuk Lymphoma; 2007 Oct; 48(10):1931-9. PubMed ID: 17917961
[TBL] [Abstract][Full Text] [Related]
18. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
